EMA与Swissmedic就ICH M4Q(R2)质量指南草案公开征求意见
Swissmedic/EMA: M4Q(R2) Guideline published for Comment
EMA和Swissmedic已就ICH M4Q(R2)质量部分指南草案启动征求意见,意见提交截止2025年10月24日。该草案聚焦CTD模块2和模块3中质量相关信息的修订,覆盖化学和生物技术方式生产的原料药与制剂。ICH已于2025年5月在官网发布该草案,具体评议程序见Swissmedic和EMA网站。
The draft guideline "THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE: QUALITY M4Q(R2)" of the ICH (INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE) was published on the ICH website in May 2025, as reported in the news "ICH M4Q Guideline Updated".This new version focuses on the revision of the quality-related information in Module 2 and 3 of the CTD to capture all necessary quality-related information for the authorisation and lifecycle management of medicinal products for human use. It will apply to active substances and finished medicinal products, which can be manufactured both chemically and biotechnologically, and is intended, among other things, to promote the efficiency and effectiveness of submissions and authorisation processing.The EMA and Swissmedic have now started the consultation phases and published the draft guideline on their websites. Comments and observations on the new draft directive can be submitted until 24 October 2025. The explanations and information on the respective commenting procedures can be found on the websites of Swissmedic and EMA.
来源:ECA GMP News · gmp-compliance.org